Q&A With Dr Chao: Oncotype DX Breast Recurrence Score® and Breast DCIS Score™
CTA spoke with Calvin Chao, MD, about how the Oncotype DX® test is implemented, how results can guide treatment, its use globally, and the future of prognostic testing.
CTA spoke with Calvin Chao, MD, about how the Oncotype DX® test is implemented, how results can guide treatment, its use globally, and the future of prognostic testing.
Clinicians can use a geriatric assessment for an objective appraisal of the health status of older patients with multiple myeloma.
Cancer Therapy Advisor asked Dr Andersen about whether it is possible to improve outcomes among patients with multiple myeloma by identifying those at risk of infection among the transplant-eligible.
Does the failure of pembrolizumab in multiple myeloma clinical trials imply checkpoint inhibition is unlikely to work for patients with the disease?
TKI selection in the first line is based on risk score and TKI toxicity profile as well as the patient’s age, ability to tolerate therapy, and comorbid conditions.
Cancer Therapy Advisor asked Dr Brufsky to comment on the evolving role of endocrine-based therapy for this patient population, including combinations based on molecular and genetic profiling.
Cancer Therapy Advisor asked Dr Kumar to discuss his team’s investigation into a dexamethasone dosing schedule for reducing the rates of peripheral neuropathy.
Cancer Therapy Advisor asked Dr Shaw to discuss ALK- and ROS1-positive NSCLC, including currently available agents and ongoing research to develop additional targeted therapies.
Cancer Therapy Advisor asked Filippo Montemurro, MD, to place recent findings in context with respect to when T-DM1 might be best indicated.
Cancer Therapy Advisor interviewed Dr Dyer about recent study results relating to the retinoblastoma epigenome and an important finding about the timing of retinoblastoma development.